The relevance of this pathway in contributing to the immune response against tumor cells is sustained by the finding that patients with breast cancer bearing a mutated P2X7 receptor progressed to metastatic disease more quickly than patients with a functional P2X7 receptor [27] (Figure 1). This evidence concerns the gene P2RX7 and breast carcinoma.